Acer Therapeutics Inc. (ACER) and Strongbridge Biopharma plc (NASDAQ:SBBP) Comparison side by side

Acer Therapeutics Inc. (NASDAQ:ACER) and Strongbridge Biopharma plc (NASDAQ:SBBP), both competing one another are Biotechnology companies. We will compare their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acer Therapeutics Inc. 20 0.00 N/A -2.45 0.00
Strongbridge Biopharma plc 4 8.08 N/A 0.85 3.62

Table 1 shows the top-line revenue, earnings per share and valuation for Acer Therapeutics Inc. and Strongbridge Biopharma plc.

Profitability

Table 2 shows the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Acer Therapeutics Inc. 0.00% -65.1% -59.2%
Strongbridge Biopharma plc 0.00% 79.3% 27.2%

Volatility & Risk

Acer Therapeutics Inc.’s current beta is 2.41 and it happens to be 141.00% more volatile than S&P 500. Strongbridge Biopharma plc has a 0.42 beta and it is 58.00% less volatile than S&P 500.

Liquidity

The current Quick Ratio of Acer Therapeutics Inc. is 7.7 while its Current Ratio is 7.7. Meanwhile, Strongbridge Biopharma plc has a Current Ratio of 5.2 while its Quick Ratio is 5. Acer Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Strongbridge Biopharma plc.

Analyst Ratings

Acer Therapeutics Inc. and Strongbridge Biopharma plc Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acer Therapeutics Inc. 0 0 2 3.00
Strongbridge Biopharma plc 0 0 0 0.00

Acer Therapeutics Inc.’s upside potential is 1,371.57% at a $44 consensus target price.

Insider & Institutional Ownership

The shares of both Acer Therapeutics Inc. and Strongbridge Biopharma plc are owned by institutional investors at 60.5% and 67.1% respectively. Insiders held 0.1% of Acer Therapeutics Inc. shares. On the other hand, insiders held about 0.3% of Strongbridge Biopharma plc’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acer Therapeutics Inc. 16.33% -12.58% -7.56% -9.63% 22.47% 11.88%
Strongbridge Biopharma plc -11.21% -33.41% -34.81% -46.91% -59.34% -31.03%

For the past year Acer Therapeutics Inc. has 11.88% stronger performance while Strongbridge Biopharma plc has -31.03% weaker performance.

Summary

Strongbridge Biopharma plc beats on 5 of the 9 factors Acer Therapeutics Inc.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD). The company was founded in 2013 and is based in Cambridge, Massachusetts.

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States, Sweden, and Cayman Islands. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. It is also involved in developing Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical development for the treatment of endogenous CushingÂ’s syndrome; and Veldoreotide, a novel somatostatin analogue that is in Phase II clinical development to treat acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.